Kezar Life Sciences (KZR) Price & Analysis

Compare

473 Followers

KZR Stock Chart & Stats

$4.17

-$0.28(-4.09%)

At close: Jan 08 4:00 PM EST

$4.17

-$0.28(-4.09%)

Day’s Range― - ―

52-Week Range$3.53 - $8.45

Previous CloseN/A

Volume19.48K

Average Volume (3M)45.11K

Market Cap

$30.54M

Enterprise Value-$55.29M

Total Cash (Recent Filing)$100.85M

Total Debt (Recent Filing)$9.45M

Price to Earnings (P/E)―

Beta1.21

Next Earnings

Nov 06, 2025

EPS Estimate

-2.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.87

Shares Outstanding7,323,106

10 Day Avg. Volume52,745

30 Day Avg. Volume45,112

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.81

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-204.78

Enterprise Value/Ebitda0.79

Forecast

1Y Price Target

$6.00

Price Target Upside43.88% Upside

Rating ConsensusHold

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsKezar reported positive topline results from the PORTOLA Ph II trial of zetomipzomib in patients with AIH which demonstrate solid efficacy and safety.

Market OpportunityUpdated duration of response data from the March dataset is expected, indicating strong CR rates in AIH and supporting a blockbuster opportunity in an underserved disease.

Regulatory ProgressThe FDA lifted the partial clinical hold for zeto in AIH.

Bears Say

Development ChallengesThe development of zetomipzomib in lupus nephritis (LN) has been suspended, impacting its progress in that area.

Regulatory ConcernsA key issue for investors will be the primary endpoint and whether a histological endpoint will be required.

Kezar Life Sciences News

Kezar Life Sciences price target lowered to $5 from $7 at Wells Fargo

Wells Fargo lowered the firm’s price target on Kezar Life Sciences (KZR) to $5 from $7 and keeps...

16h ago

KZR

Kezar downgraded to Market Perform from Outperform at William Blair

William Blair analyst Matthew Phipps downgraded Kezar Life Sciences (KZR) to Market Perform from Outperform without a price...

18h ago

KZR

Kezar Life Sciences downgraded to Hold from Buy at Jefferies

Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences (KZR) to Hold from Buy with a price target of...

18h ago

KZR

Closing Bell Movers: CSX gains over 2% on earnings beat; OZK slips on miss

Credit quality in the regional banking space contributed to the skittish sentiment in the major indices on Thursday,...

1d ago

CFG

Kezar Life Sciences trading resumes

16:30 EDT Kezar Life Sciences (KZR) trading resumes Published first on TheFly – the ultimate source for real-time,...

1d ago

KZR

Kezar says interim study required by FDA would delay future zetomipzomib trials

Kezar Life Sciences (KZR) announced regulatory updates and the initiation of a process to explore a full range...

1d ago

KZR

Kezar Life Sciences to explore strategic alternatives

Kezar Life Sciences (KZR) announced regulatory updates and the initiation of a process to explore a full range...

1d ago

KZR

Kezar Life Sciences trading halted, news pending

16:01 EDT Kezar Life Sciences (KZR) trading halted, news pending Published first on TheFly – the ultimate source...

1d ago

KZR

Kezar Life Sciences Faces Uncertainty with Hold Rating Amid FDA Setback and Strategic Alternatives Exploration

Kezar Life Sciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Maury Raycroft...

18h ago

KZR

Kezar Life Sciences Faces FDA Challenges in Drug Program

Kezar Life Sciences ( ($KZR) ) has provided an update. On October 16, 2025, Kezar Life Sciences announced...

1d ago

KZR

Positive Phase 2 Trial Results and Regulatory Progress Bolster Buy Rating for Kezar Life Sciences

TD Cowen analyst Phil Nadeau has maintained their bullish stance on KZR stock, giving a Buy rating today....

2M ago

KZR

Kezar Life Sciences Advances in Autoimmune Hepatitis Trials

Kezar Life Sciences ( ($KZR) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

KZR

Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)

Cash, cash equivalents and marketable securities totaled $100.8 million as of June 30, 2025, compared to $132.2 million...

2M ago

KZR

Cautious Hold on Kezar Life Sciences Amid Zetomipzomib Developments and Market Uncertainties

H.C. Wainwright analyst Ram Selvaraju has reiterated their neutral stance on KZR stock, giving a Hold rating yesterday....

3M ago

KZR

KZR FAQ

What was Kezar Life Sciences’s price range in the past 12 months?

Kezar Life Sciences lowest stock price was $3.53 and its highest was $8.45 in the past 12 months.

What is Kezar Life Sciences’s market cap?

Kezar Life Sciences’s market cap is $30.54M.

When is Kezar Life Sciences’s upcoming earnings report date?

Kezar Life Sciences’s upcoming earnings report date is Nov 06, 2025 which is in 19 days.

How were Kezar Life Sciences’s earnings last quarter?

Kezar Life Sciences released its earnings results on Aug 13, 2025. The company reported -$1.87 earnings per share for the quarter, beating the consensus estimate of -$2.236 by $0.366.

Is Kezar Life Sciences overvalued?

According to Wall Street analysts Kezar Life Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kezar Life Sciences pay dividends?

Kezar Life Sciences does not currently pay dividends.

What is Kezar Life Sciences’s EPS estimate?

Kezar Life Sciences’s EPS estimate is -2.16.

How many shares outstanding does Kezar Life Sciences have?

Kezar Life Sciences has 7,323,106 shares outstanding.

What happened to Kezar Life Sciences’s price movement after its last earnings report?

Kezar Life Sciences reported an EPS of -$1.87 in its last earnings report, beating expectations of -$2.236. Following the earnings report the stock price went up 1.531%.

Which hedge fund is a major shareholder of Kezar Life Sciences?

Currently, no hedge funds are holding shares in KZR

Kezar Life Sciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-58.39%

Trailing 12-Months

Asset Growth

-39.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kezar Life Sciences

Kezar Life Sciences (KZR) is a biotechnology company focused on the discovery and development of novel small molecule therapies to treat unmet needs in autoimmune diseases and cancer. The company is pioneering a new approach to drug discovery using protein degradation and immunoproteasome modulation, with a pipeline that includes both preclinical and clinical-stage programs. Kezar's lead product candidate, KZR-616, is in clinical development for the treatment of multiple autoimmune diseases.

Kezar Life Sciences (KZR) Earnings & Revenues

Historic Earnings Reports

KZR Stock 12 Month Forecast

Average Price Target

$6.00

▲(43.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","8":"$8","4.25":"$4.25","5.5":"$5.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,4.25,5.5,6.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.05,4.276923076923077,4.503846153846154,4.730769230769231,4.957692307692308,5.184615384615385,5.411538461538461,5.638461538461538,5.865384615384615,6.092307692307692,6.319230769230769,6.546153846153846,6.773076923076923,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.05,4.2,4.35,4.5,4.65,4.8,4.95,5.1,5.25,5.4,5.55,5.7,5.85,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.05,4.123076923076923,4.196153846153846,4.269230769230769,4.342307692307692,4.415384615384616,4.4884615384615385,4.561538461538461,4.634615384615385,4.707692307692308,4.780769230769231,4.853846153846154,4.926923076923077,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.84,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >